Medical Management of Glaucoma in Exfoliation Syndrome.

PubMed ID: 29965902

Author(s): Michalik AZ, Kaufman PL. Medical management of glaucoma in exfoliation syndrome. J Glaucoma. 2018 Jul;27 Suppl 1:S87-S90. doi: 10.1097/IJG.0000000000000920. Review. PMID 29965902

Journal: Journal Of Glaucoma, Volume 27 Suppl 1, Jul 2018

The treatment of glaucoma in exfoliation syndrome is similar to primary open-angle glaucoma. Frequently, exfoliation glaucoma (XFG) patients require early polytherapy with topical medications. Little emphasis has been placed on tailoring treatment specifically to XFG. New outflow enhancing agents with novel mechanisms of action, such as Rho Kinase inhibition, NO signaling (both recently FDA-approved drugs) and adenosine α1-receptor stimulation, act directly on the trabecular meshwork. These agents may prove to be effective in lowering intraocular pressure and perhaps altering the pathogenesis of XFG aid in the long-term management of this disease.